- Introduction to Clinical Research Training
- Medical Education
- United Kingdom Clinical Scholars Research Training
- Vanderbilt Hall
- Financial Aid
- Office of the Registrar
- Campus Planning and Facilities
- Ombuds Office
- Committee on Microbiological Safety
- Human Resources
- HMS Foundation Funds
- Office for Academic and Clinical Affairs
- Joint Committee on the Status of Women
- The Academy
- Global Health Research Core
- Global Clinical Scholars Research Training Program
- HMA Standing Committee on Animals
- Office of Research Compliance
- Global & Community Health
- Harvard Medical School Event Calendar
- Contact @HMS
- Office of Diversity RIA Program
- The Dean's Perspective
- Department of Pathology
- Harvard Mahoney Neuroscience Institute
- OHRA Home
- Office of Research Subject Protection
- Tools and Technology
- Alumni Association
- HMS Community Values Initiative
- HMS Information Technology
- HMS TransMed Program
- Introduction to the Practice of American Medicine
- Office of Communications & External Relations
- Office of Global Education
- Shenzhen-HMS Initiative in International Education
- South American Clinical Research Training
- test page
- Safety Quality and Informatics Leadership
- Human Resources
- Jobs @ HMS
- Contact us
- Dental Medicine
- Harvard University
Keeping Healthy Bacteria Happy
May 14, 2014
Harvard Medical School investigators at Massachusetts General Hospital have identified the mechanism by which an enzyme produced in the intestinal lining helps maintain a healthy population of gastrointestinal microbes.
A team led by Richard Hodin, HMS professor of surgery at Mass General, discovered that intestinal alkaline phosphatase (IAP) promotes the growth of beneficial bacteria by blocking the previously unknown growth-inhibiting action of adenosine triphosphate (ATP) within the intestine. Their report is published in American Journal of Physiology—Gastrointestinal and Liver Physiology.
“We found that ATP is a natural inhibitor of bacteria in our intestines and that IAP promotes the growth of ‘good’ bacteria by blocking ATP,” said Hodin, who is senior author of the paper. “By helping to keep these healthy bacteria happy, IAP protects us against dangerous pathogens that can get the upper hand when the balance is disrupted.”
The beneficial bacteria and other microbes that normally populate the human digestive system contribute to the digestive process and also prevent the proliferation of any disease-causing bacteria that may be present. A drop in the number of beneficial species, which may be caused by antibiotic treatment, poor nutrition or other health conditions, can allow the population of harmful bacteria to rise, contributing to serious medical problems, including chronic diarrhea from pathogenic species such as C. difficile, inflammatory bowel disease and metabolic syndrome.
Hodin’s team previously found that IAP keeps pathogenic bacteria in the gastrointestinal tract from passing through the intestinal wall. A 2010 study in mice revealed that the enzyme plays an important role in maintaining levels of beneficial bacteria, including restoring levels reduced by antibiotic treatment. That study also showed that IAP does not directly promote bacterial growth, leaving exactly how the enzyme helps maintain the microbial population an open question that the current study was designed to explore.
A series of experiments first confirmed that mice lacking intestinal IAP had significant reductions in the populations of several important bacterial species. Hypothesizing that IAP may act by blocking a growth-inhibiting activity of one of its target molecules, the researchers tested how well bacteria in stool samples would grow in the presence of four known IAP targets. Among the tested targets, only ATP significantly reduced bacterial growth. ATP’s inhibitory effects were reversed by application of IAP.
Best known as the primary energy supply within cells, ATP also acts as a signaling molecule both inside and outside of cells. This study is the first to identify such signaling for ATP within the gastrointestinal system.
Experiments in living mice revealed that animals genetically engineered to lack IAP had 10 times the normal level of ATP within their intestines. Fasting animals, in which IAP levels would be expected to drop, also had elevated intestinal ATP. Adding ATP to the intestines of mice in which IAP activity had been inhibited reduced levels of beneficial E. coli bacteria in the animals’ digestive systems.
Taken together, the results show that ATP inhibits the growth of intestinal bacteria in mice and that IAP’s growth-promoting effects result from the enzyme’s inactivation of ATP and possibly of related molecules.
“Now we need to find out whether IAP also promotes the growth of beneficial intestinal bacteria in humans,” said Hodin. “If it does, IAP-based therapies could offer a simple and safe approach to treating the millions of patients who suffer serious health problems caused by disruptions to intestinal microbial balance.”
The study was supported by National Institutes of Health grants R01DK050623, R01DK047186 and P30DK40561 and by a Grand Challenge Exploration Grant from the Bill and Melinda Gates Foundation.
Adapted from a Mass General news release.